CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022

Table 1 Preclinical studies of CAR-NK cells presented at ASH 2022

NK cell source	Diseases	CAR binding target	Improved methods	Targets or combination	Purpose	Abstract number	Reference
iPSCs	Hematological and solid tumors	CD20, HER-2 et al	Structure modification	SLNK12-CAR structure	Efficacy	1983	[3]
iPSCs	MM	GRPC5D	Multiple targets	Daratumumab	Efficacy	1992	[4]
Healthy adult peripheral blood	MM	Dual GRPC5D/BCMA CAR	Multiple targets	/	Efficacy	3283	[5]
Healthy adult peripheral blood	AML	CD33	Multiple targets	Downregulating NKG2A	Efficacy	1991	[6]
iPSCs	AML	α3 MICA/B	Multiple targets	CD33 TriKE	Efficacy	4623	[7]
Healthy adult peripheral blood	AML	CD123	/	/	Safety	3279	[8]
Healthy adult peripheral blood	AML	FLT3 or CD33	Inhibitory CAR	Endomucin	Safety	1978	[9]
HSC-derived lymphoid progenitors	AML	CD123	Genome editing	Incomplete BCL11B suppression	Quantity	1220	[10]

iPSCs induced pluripotent stem cells, HSC hematopoietic stem cell, MM multiple myeloma, CAR chimeric antigen receptor, AML acute myeloid leukemia, TriKE Trispecific killer engager

ISSN: 1756-8722